Molecular Therapy: Oncolytics (Mar 2022)

Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer

  • Sang-In Kim,
  • Shyambabu Chaurasiya,
  • Venkatesh Sivanandam,
  • Seonah Kang,
  • Anthony K. Park,
  • Jianming Lu,
  • Annie Yang,
  • Zhifang Zhang,
  • Isabella A. Bagdasarian,
  • Yanghee Woo,
  • Joshua T. Morgan,
  • Zhirong Yin,
  • Yuman Fong,
  • Susanne G. Warner

Journal volume & issue
Vol. 24
pp. 864 – 872

Abstract

Read online

Pancreatic cancer resistance to immunotherapies is partly due to deficits in tumor-infiltrating immune cells and stromal density. Combination therapies that modify stroma and recruit immune cells are needed. Vitamin D analogs such as calcipotriol (Cal) decrease fibrosis in pancreas stroma, thus allowing increased chemotherapy delivery. OVs infect, replicate in, and kill cancer cells and recruit immune cells to immunodeficient microenvironments. We investigated whether stromal modification with Cal would enhance oncolytic viroimmunotherapy using recombinant orthopoxvirus, CF33. We assessed effect of Cal on CF33 replication using pancreas ductal adenocarcinoma (PDAC) cell lines and in vivo flank orthotopic models. Proliferation assays showed that Cal did not alter viral replication. Less replication was seen in cell lines whose division was slowed by Cal, but this appeared proportional to cell proliferation. Three-dimensional in vitro models demonstrated decreased myofibroblast integrity after Cal treatment. Cal increased vascular lumen size and immune cell infiltration in subcutaneous models of PDAC and increased viral delivery and replication. Cal plus serial OV dosing in the syngeneic Pan02 model caused more significant tumor abrogation than other treatments. Cal-treated tumors had less dense fibrosis, enhanced immune cell infiltration, and decreased T cell exhaustion. Calcipotriol is a possible adjunct for CF33-based oncolytic viroimmunotherapy against PDAC.

Keywords